Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ANTIDOTES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ANTIDOTES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ANTIDOTES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER'S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYSIS AND RECOMMENDATIONS
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNOLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 INSTALLED BASE DATA
15 VALUE CHAIN ANALYSIS
16 HEALTHCARE ECONOMY
16.1 HEALTHCARE EXPENDITURE
16.2 CAPITAL EXPENDITURE
16.3 CAPEX TRENDS
16.4 CAPEX ALLOCATION
16.5 FUNDING SOURCES
16.6 INDUSTRY BENCHMARKS
16.7 GDP RATION IN OVERALL GDP
16.8 HEALTHCARE SYSTEM STRUCTURE
16.9 GOVERNMENT POLICIES
16.1 ECONOMIC DEVELOPMENT
17 GLOBAL ANTIDOTES MARKET, BY TYPE
17.1 OVERVIEW
17.2 CHEMICAL ANTIDOTES
17.2.1 BY ANTAGONIST
17.2.1.1. ATROPINE
17.2.1.2. BUDESONIDE
17.2.1.3. BETAMETHASONE
17.2.1.4. CALCIUM GLUCONATE
17.2.1.5. DIMERCAPTOPROPANE SULPHONATE
17.2.1.6. HYDROXOCOBALAMIN
17.2.1.7. OTHERS
17.2.2 BY TOXIN/INDICATION
17.2.2.1. CYANIDES/ NITRILES
17.2.2.2. IRRITANT GASES
17.2.2.3. HYDROFLUORIC ACID
17.2.2.4. ARSENIC/ MERCURY
17.2.2.5. ORGANOPHOSPHATES
17.2.2.6. OTHERS
17.3 PHYSICAL ANTIDOTES
17.3.1 ACTIVATED CHARCOAL
17.3.2 DEMULCENTS
17.4 PHARMACOLOGICAL ANTIDOTES
17.4.1 BY ANTAGONIST
17.4.1.1. ACETYLCYSTEINE
17.4.1.2. FLUMAZENIL
17.4.1.3. LACTRODECTUS ANTIVENOM
17.4.1.4. BOTULINUM ANTITOXIN
17.4.1.5. GLUCAGON
17.4.1.6. CALCIUM
17.4.1.7. ATROPINE
17.4.1.8. CROTALINAE POLYVALENT IMMUNE FAB
17.4.1.9. HYDROXOCOBALAMIN
17.4.1.10. IDARUCIZUMAB
17.4.1.11. SODIUM BICARBONATE
17.4.1.12. VITAMINS
17.4.1.13. OTHERS
17.4.2 BY TOXIN/INDICATION
17.4.2.1. ACETAMINOPHEN/ TYLENOL/ PARACETAMOL
17.4.2.2. POTASSIUM
17.4.2.3. PARALYTICS
17.4.2.4. ANTICHOLINESTERASE
17.4.2.5. FLUORIDE INGESTION
17.4.2.6. DIGOXIN
17.4.2.7. BENZODIAZEPINES
17.4.2.8. BETA BLOCKERS AND CALCIUM CHANNEL BLOCKERS
17.4.2.9. METHOTREXATE
17.4.2.10. OPIOID ANALGESICS
17.4.2.11. NARCOTICS
17.4.2.12. ORGANOPHOSPHATE POISONING
17.4.2.13. METHANOL POISONING
17.4.2.14. HEREDITARY OROTIC ACIDURIA
17.4.2.15. ENCEPHALOPATHY
17.4.2.16. RADIATION EMERGENCY
17.4.2.17. PNEUMOCYSTIS PNEUMONIA PROPHYLAXIS
17.4.2.18. DIAGNOSTIC BRONCHOGRAMS
17.4.2.19. DIGITALIS GLYCOSIDE TOXICITY
17.4.2.20. ALCOHOL USE DISORDER
17.4.2.21. MEGALOBLASTIC ANEMIA
17.4.2.22. OTHERS
17.5 OTHERS
18 GLOBAL ANTIDOTES MARKET, BY ROUTE OF ADMINISTRATION
18.1 OVERVIEW
18.2 ORAL
18.2.1 TABLETS
18.2.2 CAPSULES
18.2.3 OTHERS
18.3 TOPICAL
18.4 INJECTABLE
18.5 INHALATION
18.6 PARENTERAL
18.7 OTHERS
19 GLOBAL ANTIDOTES MARKET, BY CLASS
19.1 OVERVIEW
19.2 BRANDED
19.3 GENERIC
20 GLOBAL ANTIDOTES MARKET, BY TOXIN/ INDICATION
20.1 OVERVIEW
20.2 ACETAMINOPHEN
20.3 ANTICHOLINERGICS
20.4 ANTICOAGULANTS
20.5 BENZODIAZEPINES
20.6 INSECT AND ANIMAL BITES
20.7 BETA-BLOCKERS
20.8 CARBAMATES
20.9 CYANIDE
20.1 HEAVY METALS
20.11 METHOTREXATE
20.12 OPIOIDS
20.13 ORGANOPHOSPHATE POISONING
20.14 METHANOL POISONING
20.15 HEREDITARY OROTIC ACIDURIA
20.16 ENCEPHALOPATHY
20.17 RADIATION EMERGENCY
20.18 PNEUMOCYSTIS PNEUMONIA PROPHYLAXIS
20.19 DIAGNOSTIC BRONCHOGRAMS
20.2 DIGITALIS GLYCOSIDE TOXICITY
20.21 ALCOHOL USE DISORDER
20.22 MEGALOBLASTIC ANEMIA
20.23 OTHERS
21 GLOBAL ANTIDOTES MARKET, BY GENDER
21.1 OVERVIEW
21.2 MALE
21.3 FEMALE
22 GLOBAL ANTIDOTES MARKET, BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 PRIVATE
22.2.2 PUBLIC
22.3 HOMECARE
22.4 SPECIALTY CLINICS
22.5 OTHERS
23 GLOBAL ANTIDOTES MARKET, BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 HOSPITAL PHARMACY
23.3 ONLINE PHARMACY
23.4 OTHERS
24 GLOBAL ANTIDOTES MARKET, COMPANY LANDSCAPE
24.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
24.2 COMPANY SHARE ANALYSIS: EUROPE
24.3 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
24.4 MERGERS & ACQUISITIONS
24.5 NEW PRODUCT DEVELOPMENT & APPROVALS
24.6 EXPANSIONS
24.7 REGULATORY CHANGES
24.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
25 GLOBAL ANTIDOTES MARKET, SWOT AND DBMR ANALYSIS
26 GLOBAL ANTIDOTES MARKET, BY REGION
GLOBAL ANTIDOTES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
26.1 NORTH AMERICA
26.1.1 U.S.
26.1.2 CANADA
26.1.3 MEXICO
26.2 EUROPE
26.2.1 GERMANY
26.2.2 FRANCE
26.2.3 U.K.
26.2.4 HUNGARY
26.2.5 LITHUANIA
26.2.6 AUSTRIA
26.2.7 IRELAND
26.2.8 NORWAY
26.2.9 POLAND
26.2.10 ITALY
26.2.11 SPAIN
26.2.12 RUSSIA
26.2.13 TURKEY
26.2.14 NETHERLANDS
26.2.15 SWITZERLAND
26.2.16 REST OF EUROPE
26.3 ASIA-PACIFIC
26.3.1 JAPAN
26.3.2 CHINA
26.3.3 SOUTH KOREA
26.3.4 INDIA
26.3.5 AUSTRALIA
26.3.6 SINGAPORE
26.3.7 THAILAND
26.3.8 MALAYSIA
26.3.9 INDONESIA
26.3.10 PHILIPPINES
26.3.11 VIETNAM
26.3.12 REST OF ASIA-PACIFIC
26.4 SOUTH AMERICA
26.4.1 BRAZIL
26.4.2 ARGENTINA
26.4.3 PERU
26.4.4 COLOMBIA
26.4.5 VENEZUELA
26.4.6 REST OF SOUTH AMERICA
26.5 MIDDLE EAST AND AFRICA
26.5.1 SOUTH AFRICA
26.5.2 SAUDI ARABIA
26.5.3 UAE
26.5.4 EGYPT
26.5.5 KUWAIT
26.5.6 ISRAEL
26.5.7 REST OF MIDDLE EAST AND AFRICA
26.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
27 GLOBAL ANTIDOTES MARKET, COMPANY PROFILE
27.1 PFIZER INC.
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 AKORN OPERATING COMPANY LLC
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 HIKMA PHARMACEUTICALS USA INC
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 BTG INTERNATIONAL INC.
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 MERCK KGAA
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 WELLSTAT THERAPEUTICS CORPORATION
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 GHANSHYAM CHEMICALS
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 LIVEALTH
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 FLAGSHIP BIOTECH INTERNATIONAL PVT LTD
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 SPECTRUM PHARMACEUTICALS, INC.
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 FRESENIUS KABI PVT. LTD.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 CHEPLAPHARM ARZNEIMITTEL GMBH
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 HOPE PHARMACEUTICALS
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 AMERICAN REGENT, I3NC.
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 EMERGENT BIOSOLUTIONS INC.
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
27.16 CHIESI USA, INC.
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPMENTS
27.17 MALLINCKRODT.
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPMENTS
27.18 ALKERMES, INC.
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPMENTS
27.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPMENTS
27.2 VINS BIOPRODUCTS LTD
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPMENTS
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
